Cassiar Gold Corp. (TSXV:GLDC)

G1 Therapeutics Income Statement

Financials in millions CAD. Fiscal year is October - September.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020
Cost of Revenue	-	-	-	-	0.02	0.07
Gross Profit	-	-	-	-	-0.02	-0.07
Selling, General & Admin	1.45	1.63	1.83	1.56	1.84	1.56
Other Operating Expenses	0.1	0.11	0.07	0.03	0.03	-
Operating Expenses	8.33	8.71	13.4	3.07	2.54	2.52
Operating Income	-8.33	-8.71	-13.4	-3.07	-2.56	-2.59
Interest Expense	-	-	-	-	-	-0.02
Interest & Investment Income	0.26	0.25	0.22	0	-	-
Other Non Operating Income (Expenses)	0.74	0.93	0.76	0.33	0.96	0.16
EBT Excluding Unusual Items	-7.33	-7.53	-12.42	-2.75	-1.6	-2.45
Pretax Income	-7.33	-7.53	-12.42	-2.75	-1.6	-2.45
Net Income	-7.33	-7.53	-12.42	-2.75	-1.6	-2.45
Net Income to Common	-7.33	-7.53	-12.42	-2.75	-1.6	-2.45
Shares Outstanding (Basic)	125	112	88	69	54	28
Shares Outstanding (Diluted)	125	112	88	69	54	28
Shares Change (YoY)	28.02%	27.39%	27.69%	27.07%	96.31%	72.64%
EPS (Basic)	-0.06	-0.07	-0.14	-0.04	-0.03	-0.09
EPS (Diluted)	-0.06	-0.07	-0.14	-0.04	-0.03	-0.09
Free Cash Flow	-6.91	-8.16	-13.77	-10.63	-7.7	-3.01
Free Cash Flow Per Share	-0.06	-0.07	-0.16	-0.15	-0.14	-0.11
EBITDA	-8.22	-8.56	-13.29	-3	-2.47	-2.01
D&A For EBITDA	0.11	0.15	0.11	0.08	0.09	0.59
EBIT	-8.33	-8.71	-13.4	-3.07	-2.56	-2.59

Source: S&P Global Market Intelligence. Standard template. Financial Sources.